200 results about "Infectious Disorder" patented technology

The invention provides a bacillus thuringiensis strain, a fermentation culture method and application of the bacillus thuringiensis strain. The strain is preserved in the China Center for Type Culture Collection on September 28, 2011, the preservation address is No. 299 on eight road, Wuchang District, Wuhan City, Hubei Province, the preservation number is CCTCC No: M 2011334, and the preservation date is September 28, 2011. The strain cultured by the fermentation method has efficient, specific and stable insecticidal activity on culex, aedes and other mosquitoes, has the advantages of low preparation cost, environmental friendliness and the like, can be developed into a biological insecticide for preventing and killing mosquitoes and preventing and controlling malaria, dengue fever, chikungunya and other mosquito-borne infectious diseases, and meets the requirements of green and safe prevention and control in China.

Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and / or diagnose cancerous or infectious disorders.

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and / or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime / boost vaccination strategy.

The invention discloses a sheep infectious disease number zero individual tracing method and system based on a group interaction network, particularly relates to the technical field of agricultural informatization, and is used for solving the problem of number zero individual misjudgment caused by neglecting group dynamic behaviors in an existing static network model. The method comprises the following steps: dividing a continuous time window to construct a time sequence interaction network by acquiring dynamic contact data and high-risk medium use data of a sheep flock; virtual edges are added to individuals with the use interval smaller than the pathogen survival time of the same high-risk medium; calculating a node behavior mode mutation degree based on a medium using interval variance, and analyzing propagation fluctuation in combination with an input / output propagation flow ratio standard deviation; identifying nodes of which behavior mutation exceeds a threshold value, propagation fluctuation continuously exceeds the threshold value and output propagation flow suddenly drops as an abnormal propagation source; and extracting a first window associated sub-network, and judging the node which has the highest behavior mutation degree and uses a high-risk medium in the sub-network as a zero individual, thereby realizing accurate tracing of the sheep infectious disease source and providing a basis for accurate prevention and control of a farm.

The invention discloses a mosquito distribution prediction method and system, a storage medium and equipment, and relates to the technical field of data processing, and is used for predicting the mosquito distribution state, and the method comprises the steps: synchronously collecting environment data and mosquito population data, carrying out the time-space alignment, building a nonlinear correlation model through combining a bidirectional LSTM model and transfer learning, and carrying out the prediction of the mosquito distribution state. Complex nonlinear correlation between environmental factors and mosquito population dynamics can be accurately captured; mosquito distribution of different time scales is predicted by using a graph neural network and a Transform architecture, and accurate modeling of a multi-scale space-time interaction rule of mosquito distribution is realized. The prediction result is calibrated through a deviation correction mechanism, the temporal-spatial resolution and accuracy of mosquito distribution prediction are remarkably improved, and reliable data support is provided for accurate prevention and control of insect-borne infectious diseases.

The invention relates to the technical field of image or video recognition or understanding, and discloses an areca yellows early warning method based on regular economic forest multi-dimensional symptom analysis, in the method, the unique morphology of areca and various morphological changes which are invisible under trees but visible in remote sensing during the period that areca suffers from yellows are fully utilized, and the areca yellows early warning effect is achieved. And the multiple symptoms are combined to form a multi-symptom matching degree, so that the misrecognition problem can be eliminated in an auxiliary manner when specific symptoms exist. When the specific symptoms do not exist, whether the disease of the current areca-nut forest belongs to the infectious disease or not is indirectly judged according to the distribution characteristics of the multi-symptom matching degree in time and space by utilizing the distribution characteristics and the disease course development rule when the areca-nut is cultivated as an economic arbor, and if yes, the disease of the current areca-nut forest belongs to the infectious disease; and considering that the areca yellows occupy a large proportion in the areca infectious diseases, the pathogen detection cannot be infeasible due to entrainment of a large number of irrelevant diseased plant samples when the pathogen detection is carried out at the moment. The above points are combined to realize early warning of areca yellows.

Bartonellosis is an emerging group of infectious diseases caused by bacteria belonging to the genus Bartonella, which includes at least 22 named species of bacteria transmitted primarily by carriers (i.e., vectors) including fleas, pubic lice, nits, sand flies, ticks, and potentially mites and spiders. In some aspects, the present disclosure provides antigen-specific amino acid sequences of Bartonella.

The present invention relates to formula (I): [Formula 1] A compound of TIFF2026514449000425.tif27170, or its tautomers, stereoisomers, salts, solvates, or N-oxides, wherein A 1 ~A 6 X, Y, R 7a , R 7b , R 8a , and R 8b The claims are as defined. The present invention further relates to pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, and their uses as agents, in particular as agents having METTL3 inhibitory activity, and advantageously for use in the treatment or prevention of cancer, or autoimmune diseases, neurological diseases, infectious diseases, or inflammatory diseases.

The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.

The present invention relates to certain compounds that function as inhibitors of DHX9 activity (RNA Helicase A / RHA or Nuclear DNA Helicase II / NDH II). The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions 5 comprising them, and to their use in the treatment of proliferative disorders, such as cancer, autoimmune and infectious diseases, as well as other diseases or conditions in which DHX9 activity is implicated.

An air handling unit of an HVAC system of a building including ducting through which airflow is controllably pushed by a supply fan of the HVAC system, at least one of a heating or cooling device within the ducting, an air handling unit controller configured to control operation of the at least one of the heating or cooling device within the ducting to generate condensation from air flowing through the air handling unit, and a collector tray placed within and / or integrated with the ducting below the at least one of the heating or cooling device and structured to collect the condensation, via gravity, for use in analysis of the condensation, wherein the at least one of the heating or cooling device, the air handling unit controller, and the collector tray are configured to collect the condensation including infectious disease particles from the air flowing through the air handling unit.

The present invention relates to an antifungal prodrug comprising an antifungal moiety linked to a trigger moiety by means of a self-immolative spacer. The trigger moiety is selected from a glycosyl residue and an oligosaccharide, stabilizing the self-immolative spacer and enabling cleavage by a pathogen hydrolase, preferably an extracellular glycosidase (EC 3.2.1). Upon cleavage of the trigger moiety by the pathogen hydrolase, the self-immolative spacer undergoes spontaneous degradation in order to release the antifungal moiety. The present invention further relates to pharmaceutical compositions comprising the prodrug and to the use thereof in the treatment of infectious diseases.

The present invention relates to nucleic acids and related immunogenic polypeptides for the prevention or treatment of infectious diseases. In particular, nucleic acids and immunogenic polypeptides provide utility for the prophylactic prevention of norovirus infection in mammals. The invention further relates to nucleic acid-based vaccine compositions and partial kits comprising the vaccine compositions, as well as therapeutic methods and medical uses related to the nucleic acids, vaccine compositions and partial kits.

Provided are silicon-containing compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein n, R1, R2, and ring A are described herein, which are useful as antivirals, pharmaceutical compositions comprising the same, and use thereof in the treatment of viral infectious disease or conditions.

The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

The present application relates to a kind of cat rhinotracheitis, feline calicivirus disease, cat pancytopenia triple subunit vaccine, preparation method and its application.The present application is expressed antigen protein using CHO cell strain, and synergistic effect is combined molecular adjuvant (IL-2, GM-CSF, CpG) with MF59 nanoemulsion, molecular adjuvant composition is adsorbed on the surface of MF59 nanoemulsion, then embedded in polylactic acid-glycolic acid copolymer microsphere, mixed with triple subunit protein to form vaccine preparation.The vaccine prepared in the present application can stimulate humoral immunity and cellular immunity simultaneously by subcutaneous or intramuscular injection, significantly improve antibody titer and attack protection rate, prolong immune protection period, and reduce injection site adverse reactions.The synergistic effect of protein and molecular adjuvant and MF59 makes the vaccine superior to traditional subunit vaccine in safety, stability and immunological efficacy, and is suitable for high-efficiency prevention of three viral infectious diseases in feline.

The application provides a primer probe set, a kit and application for quantitatively detecting murine infectious agents, and belongs to the technical field of genetic engineering.The six-reagent quantitative detection kit (fluorescent PCR method) for tsutsugamushi oriental body, fever with thrombocytopenia syndrome virus, prrillonella, hantavirus, leptospira, and rickettsia mooseri can detect the six pathogenic targets of tsutsugamushi oriental body, fever with thrombocytopenia syndrome virus, prrillonella, hantavirus, leptospira, and rickettsia mooseri in one reaction, and accurately quantitatively analyzes each pathogenic target.Through single-tube reaction, parallel detection and quantification of the six pathogenic targets are realized, the time consumed due to misjudgment of the targets is reduced, the consumption of consumables and the occupation of instrument space caused by multi-tube reaction are reduced.The quantitative results reflect the pathogenic load, and provide efficient detection and application support for rapid identification and quantitative monitoring of samples of murine origin or samples of the environment related to mouse activities.

Lipidized oxoadenines of formula (I) are TLR7 / 8 receptor ligands useful for modulating immune responses. These compounds may have therapeutic applications in the treatment of cancer, infectious diseases, allergies, or autoimmune disorders (SEE FORMULA).

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Despite the existence and deployment of a range of antimicrobial / disinfectant / sterilization technologies and products, transmission of infectious diseases remains a significant problem worldwide, continuing to cause hundreds of millions of infections and millions of deaths every year of both human beings and animals. State-of-the-art technologies suffer from several disadvantages including being discrete in space and time, being overly dependent on human skill and discipline, and in some cases having harmful side-effects to human health. This invention proposes a series of industrial grade antimicrobial product designs, and materials and methods to make them highly effective products that offer continuous antimicrobial action, with minimum dependence on human discipline and skill once deployed, and with no harmful side-effects. Methods may include either or both first and second materials be formed by vapor or solution-based coating schemes and many may be antimicrobial in nature. Nanopores and / or nanotubes produce an ultra-high anti-microbially active surface area.

Lipidated oxoadenines of formula (I) are TLR7 / 8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmune disorders.

The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5′ copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5′ copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and / or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.

There is provided a drug which exhibits preventive and therapeutic effects on virus infectious diseases by inhibiting virus-derived protease on the basis of various physiological activity actions of an active sulfur compound(s) which exists in living organisms.

The application discloses a modified crRNA, a light-controlled nucleic acid detection system, a kit and application, and belongs to the cross field of biotechnology, intelligent sensing and molecular diagnosis. In view of the technical defects of strong target sequence dependence and high ultraviolet irradiation requirement of the existing light-controlled CRISPR technology, the application innovatively introduces a photosensitive protection group 6-nitropiperidin oxymethyl (NPOM) at a specific key node of a stem loop skeleton of crRNA maintaining conformation. In the constant temperature amplification stage, preferred double-site cooperative modification can transiently inhibit RNP complex assembly to realize target non-interference enrichment; subsequently, only 10 mW / cm 2 of extremely low intensity ultraviolet light irradiation for 30 seconds can restore the crRNA conformation and activate the trans cleavage. The preferred technical scheme of the application can eliminate the target sequence limitation, realizes a detection limit of as low as 2 copies in a single reaction tube, and the result can be obtained within 15 minutes. The system is widely applicable to rapid diagnosis of infectious agents, high-specificity typing of single nucleotide polymorphism and portable intelligent molecular diagnosis terminal.

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

This application relates to pyrimidine derivatives described in formula (I-1), formula (I-2), formula (II-1), or formula (II-2), or their stereoisomers, tautomers, isotopic derivatives, hydrates, solvates, prodrugs, and pharmaceutically acceptable salts, which can be used as effective TLR7 and / or TLR8 receptor agonists and are characterized by good selectivity, high activity, and excellent safety. This application also provides a method for preparing the pyrimidine derivatives and a pharmaceutical composition thereof. The compounds of this application or their pharmaceutical compositions can be used in the preparation of pharmaceuticals for the prevention or treatment of infectious diseases, respiratory diseases, immune-related diseases, viral diseases, or tumors. TIFF2026528992000173.tif3891

The present invention relates to a phage-based gene delivery system targeting human cells or animal cells, including immune cells, other human cells and cancer cells. In particular, the present invention relates to novel phage particles and associated phagemid expression systems and their production for the delivery of transgenes, comprising DNA encoding pathogen antigens, to human immune cells, suitable for use in vaccines and vaccine development against infectious diseases and cancers.

Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and / or diagnose cancerous or infectious disorders.

The present invention relates to a compound of formula (I) [Formula 1] JPEG2026502845000045.jpg42170 (wherein L represents a linker, W 1 , W 2 , X 1-5 , x, m, n and R 1-4 The present invention relates to novel linker-drug compounds based on specific phosphoantigens (pAgs) having the general structure reflected in (wherein R is as defined herein). Also provided are conjugates comprising a targeting moiety, preferably a tumor-targeting antibody or antigen-binding fragment thereof, covalently attached to the linker-drug compounds of the invention. The conjugates can be used, for example, to treat diseases such as cancer, infectious diseases, and autoimmune diseases.

The invention discloses application of a triple-helix structural element in RNA (Ribonucleic Acid) drug design, and belongs to the field of biological medicines. According to the application, an ENE element or a mutant of the ENE element is used as a nucleic acid stabilizing element, and the interaction between 3 'UTR and poly (A) is optimized, so that the mRNA stability is enhanced, and the protein translation efficiency is further improved, and therefore, the problem of low protein expression quantity in RNA therapy is effectively solved. The mRNA sequence optimization strategy provided by the invention provides a new method for vaccine design in the field of infectious disease and tumor immunotherapy, and has a wide application prospect.